How Tirzepatide Works: The Dual GLP-1/GIP Mechanism

For most of the modern history of obesity pharmacology, the goal was to find one good target and hit it well. GLP-1 turned out to be that target, and the medications built on it — semaglutide foremost among them — reset what weight-loss drugs could be expected to do. Tirzepatide did something different. Rather than activating a single gut-hormone receptor, it activates two at once: the GLP-1 receptor and the receptor for a second incretin called GIP. It is a dual agonist, a single engineered molecule with two jobs, and in the trials that magnitude of weight loss exceeded what GLP-1 alone had produced.

That result is the reason tirzepatide is interesting, and the reason its mechanism is worth understanding in detail. Why would adding a second receptor help? What does GIP actually do, given that its role in body weight has been genuinely confusing to researchers for years? And how much of the extra weight loss is attributable to GIP itself versus the simple fact of building a more potent molecule? This page works through the dual mechanism, the evidence behind it, and what it means in practice. It is part of the broader GLP-1 science guide, and sits within the GLP-1 science cluster alongside the comparison and trial pages it draws on.

Two Incretins, One Molecule

The body uses gut hormones to coordinate what happens after a meal. The two principal incretins — hormones that amplify insulin release when glucose arrives through the digestive tract — are GLP-1 and GIP. GLP-1 (glucagon-like peptide-1) is released by L-cells in the lower small intestine and colon. GIP (glucose-dependent insulinotropic polypeptide) is released earlier, by K-cells in the upper small intestine. Both rise after eating, and both tell the pancreas to release more insulin than the same glucose load would trigger if it bypassed the gut. The deeper contrast between the two hormones is laid out in the difference between GLP-1 and GIP.

Native versions of both hormones share a practical problem that kept them from becoming drugs for decades: they are degraded within minutes by the enzyme DPP-4. The pharmacological achievement behind every medication in this class is engineering a version that survives long enough to be useful. Tirzepatide is a synthetic peptide built around a GIP-like backbone, modified with a fatty-acid chain that binds to albumin in the blood — the same trick that lets it circulate for roughly a week per dose, supporting once-weekly injection. Crucially, the single molecule is shaped to fit and activate both receptors. It is not a mixture of two drugs; it is one peptide doing two things.

The active ingredient is sold under two brand names for two indications: Mounjaro for type 2 diabetes and Zepbound for weight management. As with semaglutide's brand split, the molecule is identical — the labels differ, not the drug — a distinction unpacked in Mounjaro versus Zepbound.

What the GLP-1 Side Does

Half of tirzepatide's mechanism is the familiar GLP-1 action, and it is worth restating because it carries most of the load that is well understood. Daniel Drucker's 2018 synthesis in Cell Metabolism describes the four core effects of GLP-1 receptor activation: it stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon, slows gastric emptying, and acts centrally on the brain to enhance satiety.

For weight specifically, the appetite effects matter most. Slowed gastric emptying keeps the stomach distended longer after a meal, extending fullness. In the hypothalamus, GLP-1 receptor activation biases the arcuate nucleus — the brain's appetite thermostat — toward satiety. And in the reward system, GLP-1 agonism quiets the response to food cues: van Bloemendaal and colleagues showed in 2014, using functional MRI, that GLP-1 receptor activation reduced activation in reward-related regions such as the insula and orbitofrontal cortex in response to food images, with the effect specific to food rather than a general blunting of motivation. This is the neurobiological basis of what patients describe as reduced "food noise." The same GLP-1 machinery, and how it produces weight loss on its own, is covered in how semaglutide works for weight loss.

If tirzepatide simply added GIP on top of a fully effective GLP-1 component, the interesting question would be what GIP contributes. But the molecule is not balanced one-to-one between the two receptors, which is part of why isolating GIP's specific contribution has proven difficult.

The GIP Puzzle

GIP is where the story stops being tidy. Like GLP-1, GIP is an incretin that amplifies glucose-dependent insulin secretion, so its blood-sugar role is straightforward enough. Its role in body weight, however, has been one of the more genuinely paradoxical questions in metabolic research.

For years, the prevailing view from animal work was that GIP promotes fat storage — and that blocking GIP signalling protects against weight gain. Mice lacking the GIP receptor resist diet-induced obesity. On that logic, a GIP receptor antagonist should help with weight, not an agonist. Yet tirzepatide, the most effective obesity drug yet brought to market, works in part by activating the GIP receptor. Both directions — agonism and antagonism — have shown weight-loss potential in different experimental settings, which is an unusual and uncomfortable situation for a field that prefers its mechanisms to point one way.

The leading reconciliation is that sustained, high-level GIP receptor agonism may ultimately desensitise or downregulate the receptor, producing a functional state that resembles antagonism. On this view, persistently switching the receptor on hard ends up turning its signalling down — so "agonism" and "antagonism" converge on a similar endpoint. This remains a hypothesis under active investigation, not settled fact.

There is also a central component. GIP receptors are expressed in regions of the brain involved in appetite and nausea, and some evidence suggests GIP receptor activation in the brain may both contribute to appetite suppression and blunt the nausea that GLP-1 agonism tends to provoke. If that holds, GIP would be doing two useful things at once: adding to the satiety signal and improving tolerability, potentially allowing more of the GLP-1 effect to be delivered before side effects force a halt. This is mechanistically attractive and consistent with the clinical picture, but it should be read as a working model rather than a proven account.

Why Dual Agonism May Outperform GLP-1 Alone

The honest framing is that the clinical superiority of tirzepatide is well established, while the precise reason is not fully resolved. Several non-exclusive explanations are on the table, and the truth is probably a combination.

• GIP adds an independent appetite signal. If GIP receptor engagement contributes to satiety through pathways GLP-1 does not fully cover, then hitting both receptors recruits more of the body's post-meal signalling than hitting one — an additive effect.
• GIP improves tolerability, allowing a bigger GLP-1 effect. If GIP agonism dampens nausea, patients may tolerate a more aggressive overall signal, so more of the appetite suppression actually lands rather than being capped by side effects.
• The dual molecule simply achieves a more favourable signalling profile. It is possible that the specific pharmacology of the engineered peptide — its potency, balance, and receptor kinetics — produces a better result somewhat independently of any tidy "GLP-1 plus GIP" arithmetic.

What matters clinically is that engaging both pathways outperforms engaging GLP-1 alone, whatever the underlying reason. The head-to-head and trial evidence bears this out, and for anyone weighing the two leading drugs against each other, the practical comparison is set out in the tirzepatide versus semaglutide comparison.

What the SURMOUNT Trials Show

The evidence that anchors tirzepatide's reputation is the SURMOUNT programme. SURMOUNT-1, led by Ania Jastreboff at Yale and published in the New England Journal of Medicine in 2022, randomised 2,539 adults with obesity — or overweight with a weight-related complication, and without diabetes — to one of three tirzepatide doses (5mg, 10mg, or 15mg) or placebo over 72 weeks. Mean weight loss was 15.0% on the 5mg dose, 19.5% on 10mg, and 20.9% on the highest 15mg dose, against 3.1% on placebo. On the top dose, the average participant lost roughly a fifth of their starting body weight, and more than half of those on 15mg lost more than 20% — figures that overlap, at the high end, with what bariatric surgery has typically achieved. The fuller breakdown sits in the Zepbound clinical trial results.

The contrast with GLP-1 monotherapy is the relevant benchmark. In the comparable STEP 1 trial — Wilding and colleagues, also in the NEJM — once-weekly semaglutide titrated to 2.4mg produced a mean weight loss of about 14.9% over 68 weeks. The trials differ in design and population, so this is not a formal head-to-head, but the gap between roughly 15% for GLP-1 alone and roughly 21% for the dual agonist at top dose is large and consistent enough to be taken seriously. Direct comparison trials of the two molecules have since reinforced the same ordering.

Two caveats from the trial literature apply with full force here. First, the weight loss was achieved while taking the medication — the trials describe what the drug does during treatment, not after it. Second, averages conceal wide individual variation: some participants lost a great deal, others relatively little, and a minority did not respond meaningfully. The SURMOUNT numbers establish what is possible at the population level, not what any one person should expect.

Drug	Receptors	Defining trial	Mean weight loss (top dose)
Semaglutide	GLP-1	STEP 1 (68 wk)	~14.9%
Tirzepatide	GLP-1 + GIP	SURMOUNT-1 (72 wk)	~20.9%

Practical Implications

The dual mechanism shapes how tirzepatide is used, not just how well it works. Because the GLP-1 component slows gastric emptying just as semaglutide's does, the dominant side effects are gastrointestinal — nausea, diarrhoea, constipation, and early fullness — generally mild to moderate and concentrated early in treatment. This is why titration is non-negotiable: tirzepatide is started low (typically 2.5mg) and stepped up over months, letting the gut adapt at each level before the dose rises. Rushing the schedule is one of the most common reasons people experience side effects severe enough to stop. The behavioural strategies that help — smaller, slower, lower-fat meals and good hydration — are the same as for any drug in the class.

Reduced intake also raises the familiar concern about protein and lean mass. When appetite falls this much, protein is often the macronutrient that suffers, and inadequate protein during rapid weight loss accelerates the loss of muscle alongside fat. Deliberate protein intake and resistance training are the standard countermeasures, and they matter more, not less, at the larger magnitudes of weight loss tirzepatide produces.

The most consequential practical point concerns what happens after stopping, and it is not specific to tirzepatide — it follows from the biology of body weight. The body defends its prior weight: Sumithran and colleagues showed in 2011 that appetite-regulating hormones remain dysregulated in the direction favouring regain a full year after weight loss, while Leibel's work demonstrated that resting energy expenditure falls more than body-size change alone predicts. Müller's 2018 synthesis describes a system that resists downward shifts in weight through coordinated changes in hunger, satiety, and energy expenditure, and Anderson's meta-analysis found people retained only about 23% of their lost weight at five years across studies. Against that backdrop, the STEP 4 trial (Rubino, 2021) showed that switching semaglutide to placebo led to regain of roughly two-thirds of lost weight over the following year, and the STEP 1 extension (Wilding, 2022) found the same pattern. Tirzepatide counters the body's defence of its weight for as long as it is present; the evidence to date gives no reason to expect it behaves differently on withdrawal. The closer analogy is medication for blood pressure than a course of antibiotics.

It is also worth naming what the dual mechanism does not change. Tirzepatide is not a stimulant; the appetite reduction arrives as diminished interest in food rather than a revved-up feeling. And the reward-circuit effect that Volkow's imaging work locates at the heart of food reinforcement is engaged through the GLP-1 side, not invented anew by GIP — the dual agonist turns down the gain on the same circuitry, arguably more strongly, rather than acting on a different one.